|Year : 2018 | Volume
| Issue : 1 | Page : 55-58
The effectiveness of Melissa officinalis on sleep problem in patients with chronic heart failure
Fatemeh Aliakbari1, Mahmoud Rafieian2
1 Department of Nursing, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
|Date of Web Publication||21-Aug-2018|
Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Numerous studies have documented high prevalence rate of major depression in patients with heart failure. The aim of the present study was to evaluate the effectiveness of Melissa officinalis on sleep problem in patients with chronic heart failure (CHF). Materials and Methods: In a randomized, controlled trial study, eighty patients (40 in each group) with CHF experiencing insomnia were allocated randomly into intervention and control groups. The patients in intervention group received 12 ml M. officinalis syrup in addition to conventional treatment 1 h before going to bed for 4 weeks. A demographic questionnaire and the Pittsburgh Sleep Quality Index were used to collect data. Questionnaires were completed by all individuals before and after the intervention. Results: The time duration of waiting for falling into sleep in intervention group was significantly less than control group (P = 0.001). The hours during which the individuals were fully asleep were significantly more than control group (P < 0.05). Conclusion: M. officinalis may improve the quality of sleep in patients with CHF who experience insomnia.
Keywords: Heart failure, Melissa officinalis, sleep
|How to cite this article:|
Aliakbari F, Rafieian M. The effectiveness of Melissa officinalis on sleep problem in patients with chronic heart failure. J Pharm Negative Results 2018;9:55-8
|How to cite this URL:|
Aliakbari F, Rafieian M. The effectiveness of Melissa officinalis on sleep problem in patients with chronic heart failure. J Pharm Negative Results [serial online] 2018 [cited 2020 May 31];9:55-8. Available from: http://www.pnrjournal.com/text.asp?2018/9/1/55/239507
| Introduction|| |
Sleep problem is a common problem in patients with chronic heart failure (CHF) and is a significant contributing factor to fatigue and poor quality of life. The pathophysiology of CHF often leads to fatigue, due to nocturnal symptoms causing sleep disruption, including cough, orthopnea, paroxysmal nocturnal dyspnea, and nocturia. The presence of insomnia symptoms, despite the stable condition in patients who suffered from heart failure and received evidence-based management, suggests that this management alone is not sufficient to decrease insomnia symptoms. Only about 10% of these patients receive adequate treatment. Conventional approaches to the treatment of chronic insomnia usually involve either pharmacotherapy or psychological interventions. Pharmaceutical hypnotics are the primary first-line pharmacotherapy used to treat chronic insomnia.
Benzodiazepines are the most effective and utilized drugs used to combat insomnia. The consumption of these drugs, especially in prolonged use has the potential serious adverse effects  such as dependence, rebound insomnia, bad sleep quality, negative consequences for cognitive functions, and decreased effectiveness, which has led to search for safe alternative treatments among herbal products. Complementary and alternative medicine (CAM) may be useful for management of insomnia in older adults. The 2003 National Sleep Disorders Research Plan emphasis on the importance of studies that evaluating CAM therapies for sleep problems. Interest in the use of alternative therapies and products for insomnia has grown over the past two decades due to range of motivational factors. Many patients prefer “natural remedies” for the treatment of their diseases because they think that remedies have low adverse effects and interactions and do not require a medical prescription.
Despite evidence of widespread interest, research evidence is lacking on the efficacy of many plant-based therapies, especially in older adults. One of the herbal medicines with sedative effect is Melissa officinalis that has been recognized since the 18th century in Europe and has since been used for sleep disorders.M. officinalis is effective in a wide variety of diseases.,,, Recent evidence suggests that M. officinalis extract, which contains rosmarinic acid and the triterpenoids oleanolic acid and ursolic acid, inhibits gamma-aminobutyric acid transaminase (GABA) activity. Sleep problems are a common problem in patients with CHF, but there are few studies investigating the effects of herbal medicines on sleep disorders in these patients. Thus, it is necessary to conduct more research in this field. The aim of the present study was to evaluate the effects of M. officinalis on sleep problems in patients with CHF.
| Materials and Methods|| |
This was a parallel group, placebo-controlled trial study that was conducted in the Cardiovascular Disease Clinic of Shahrekord, Iran, from March 2010 to November 2010. Overall coordination of the trial was conducted by Medical Plants Research Center of the Shahrekord University of Medical Sciences. Participants in the study were male and female outpatients aged older than 40 years. The study participants were patients with CHF who were conscious and communicable and had agreed to participate in the study. All participants were examined by a cardiologist, who took a patient history and performed a clinical examination. Doppler echocardiographic examinations were performed to assess left ventricular ejection fraction. Before formal inclusion in the study, participants underwent a screening interview to determine the nature and history of sleep difficulty. In addition, the researcher completed Petersburg Sleep Quality Investigation (PSQI) questionnaires to select the people with score of at least 6. Patients were excluded if they were unwilling to continue participating or having allergy or physical problems to medicines during the study. The protocol and informed consent were reviewed and approved by the Ethics Committee of the Shahrekord University of Medical Sciences. The protocol was registered in Iranian Registry of Clinical Trial (no.: IRCT 201204042289N2).
The participants were informed about the study method and assured of confidentiality and anonymity. They gave written consent and made clear that they could withdraw from the study at any time. Regarding statistical calculations, the number of population was 40 for each group; a total of 87 cases were selected for pursuing investigation. In the first step, purposeful sampling was adopted. However, patients were randomly divided into two study groups. At the end of each sampling day, each patient with inclusion criteria was characterized by 1 or 2 to be included in groups one or two, respectively. The patients in intervention group received conventional CHF treatment while taking 12 ml, M. officinalis syrup (produced by Mina-Pharmaceutical and Cosmetics Laboratory, Tehran, Iran), an hour before going to bed every night for 1 month. The control group received conventional CHF treatment and alprazolam as hypnotic drug. Data were collected through a questionnaire comprising of two sections of demography and sleep quality questionnaire.
The questions specified for sleep appraised included PSQI questionnaire, with 89.6% sensitivity and 86.5% specification. The questionnaire has been developed for investigating patient's attitude toward sleep quality within 4 weeks and bears 7 scales of general description of sleep quality by individual, delay in falling into sleep, useful sleep duration, sleep adequacy (ratio of useful sleep duration to the total time spent in bed), sleep disorders (nightly getting up), the amount of soporific medicine taken, and finally daily performance (i.e., the difficulties due to insomnia experienced by an individual during the day).
The review of the literature indicates an acceptable consistency between the questionnaires results and laboratory sleep investigation by means of polysomnography. The score for each scale is 0–3, representing natural condition, moderate to mean, and severe difficulties, respectively. The summation of 7-fold scales comprises total score, ranging from 0 to 21. The total score of 6 or more was considered as sleep quality unacceptability. Questionnaires were completed by all individuals before and after intervention. Data were analyzed using SPSS 16 (SPSS Inc, Chicago, IL, USA) with x2, paired and independent t-tests and one-way ANOVA. P < 0.05 was considered as statistically significant.
| Results|| |
In this study, 87 patients were recruited in a cardiovascular disease center in Shahrekord. However, seven people were subsequently excluded, one because of death, three due to unwillingness to take medicine, and three patients did not perform any baseline visit and thus were not eligible for evaluation. Finally, eighty patients were evaluated in two groups. There were 60 (38.2%) male patients while the rest (61.8%) were females (P > 0.05) with the mean age of 62.4 ± 9.65 years. The mean time to fall into sleep was 1.2 ± 0.96 h before intervention and 0.74 ± 0.41 h after intervention. Furthermore, the time duration of sleep at night was 0–10 h (4.54 ± 1.74 on average) before, and 2–8 h(5.38 ± 1.05 on average) after intervention, respectively (P < 0.05). The results obtained before intervention indicated that there were no significant differences regarding the time of falling into sleep, time duration of waiting for falling into sleep, and the number of hours during which the individuals were fully asleep as well as sex and age distribution (P > 0.05). Besides that, the samples were normally distributed between the two groups.
The time duration of waiting for falling into sleep was significantly less in intervention group (P = 0.001). In addition, the hours during which the individuals were fully asleep were significantly more than those on the control group (P < 0.05). In the present study, before intervention, there was no significant difference between two groups in total score of quality of sleep (P = 0.239). However, after intervention, control group had lower score in comparison to intervention group [Table 1].
| Discussion|| |
The most notable finding of the current study was that M. officinalis is effective in causing significant improvements in important sleep parameter in patients with CHF. Findings showed improvement of sleep quality in intervention group compared to control group. Scientific evidence related to the efficacy of valerian is inconclusive. The current study is one of the few randomized placebo-controlled trials evaluating treatment of insomnia using medicinal plants among CHF patients. Some systematic reviews on the efficacy of valerian on insomnia have been performed, but they reach different conclusions.
In a previous study, Wheatley et al. found that stress decreased significantly after daily taking of 600 mg valerian during 6 months. Besides, the patient's insomnia was considerably improved. In another study, Giedke H et al. found that the patient's sleep improved significantly after valerian taking for several days. Moreover, there was a significant decrease in sleep latency time in intervention group in recent study. The same result was achieved in Leathwood and Chauffard. that demonstrated that the group taking valerian achieved an improvement in sleep quality compared to the placebo group. In addition, the sleep latency time, as well as nightly getting up frequency was decreased.
The use of 450 mg valerian at bedtime in improving sleep in patients who are undergoing treatment for cancer in study of Barton could not improve sleep as measured by the PSQI.
Morin in a clinical trial study assessed valerian-hops combination and diphenhydramine for treating insomnia. The result showed that valerian produced slightly greater, though nonsignificant, reductions of sleep latency relative to placebo and diphenhydramine at the end of 14 days of treatment and greater reductions than placebo at the end of 28 days of treatment.
Recently, Shinomiya et al. reported that a significant shortening in sleep latency without any significant effects on the total duration of wakefulness was observed with valerian extract. Although GABA is present in valerian extracts, its brain bioavailability through oral administration is uncertain. The action of valerian on the central nervous system might be due in part to GABA involvement through a number of mechanisms, including inhibition of GABA uptake into synaptosomes. Valerian constituents inhibit the enzymatic breakdown of GABA and enhance benzodiazepine binding. The other potential mechanisms for the pharmacological activity of valerian have been proposed, including partial agonistic activities on 5-HT5a receptor.
| Conclusion|| |
The results of this study support the hypothesis that valerian can improve sleep quality in patients with CHF. Because of fewer side effects of herbal medicines, these products can be taken as a safe substitute for synthetic medicines.
This study was funded by the Medical Plants Research Center of the Shahrekord University of Medical Sciences. The protocol and informed consent document were reviewed and approved by Ethics Committee of Shahrekord University of Medical Sciences and IRCT201204042289N2 was issued for the study by Iranian Registry of clinical Trials.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Broström A, Johansson P. Sleep disturbances in patients with chronic heart failure and their holistic consequences-what different care actions can be implemented? Eur J Cardiovasc Nurs 2005;4:183-97.
Hayes D Jr., Anstead MI, Ho J, Phillips BA. Insomnia and chronic heart failure. Heart Fail Rev 2009;14:171-82.
Redeker NS, Jeon S, Muench U, Campbell D, Walsleben J, Rapoport DM, et al.
Insomnia symptoms and daytime function in stable heart failure. Sleep 2010;33:1210-6.
Tariq SH, Pulisetty S. Pharmacotherapy for insomnia. Clin Geriatr Med 2008;24:93-105, vii.
Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial. JAMA 1999;281:991-9.
Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008;69 Suppl E1:8-13.
Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005;66 Suppl 2:9-13.
National Center on Sleep Disorders Research (National Heart, Lung, Blood Institute), Trans-NIH Sleep Research Coordinating Committee. 2003 National Sleep Disorders Research Plan. US Dept. of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, National Center on Sleep Disorders Research, Trans-NIH Sleep Research Coordinating Committee; 2003.
Sirois FM. Motivations for consulting complementary and alternative medicine practitioners: A comparison of consumers from 1997-8 and 2005. BMC Complement Altern Med 2008;8:16.
Shayganni E, Bahmani M, Asgary S, Rafieian-Kopaei M. Inflammaging and cardiovascular disease: Management by medicinal plants. Phytomedicine 2016;23:1119-26.
Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003;290:1505-9.
Németh-Zámbori É, Pluhár Z, Szabó K, Malekzadeh M, Radácsi P, Inotai K, et al.
Effect of water supply on growth and polyphenols of lemon balm (Melissa officinalis L
.) and thyme (Thymus vulgaris L
.). Acta Biol Hung 2016;67:64-74.
Jeung IC, Jee D, Rho CR, Kang S. Melissa officinalis L. Extracts protect human retinal pigment epithelial cells against oxidative stress-induced apoptosis. Int J Med Sci 2016;13:139-46.
Joukar S, Asadipour H, Sheibani M, Najafipour H, Dabiri S. The effects of Melissa officinalis
(lemon balm) pretreatment on the resistance of the heart to myocardial injury. Pharm Biol 2016;54:1005-13.
Scholey A, Gibbs A, Neale C, Perry N, Ossoukhova A, Bilog V, et al.
Anti-stress effects of lemon balm-containing foods. Nutrients 2014;6:4805-21.
Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay-guided fractionation of lemon balm (Melissa officinalis L
.) using an in vitro
measure of GABA transaminase activity. Phytother Res 2009;23:1075-81.
Soleimani M, Masoodi R, Sadeghi T. General health and sleep quality in nurses. J Shahrekord Univ Med Sci 2008;3:70-5.
Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo G, et al.
Effectiveness of valerian on insomnia: A meta-analysis of randomized placebo-controlled trials. Sleep Med 2010;11:505-11.
Wheatley D. Stress-induced insomnia treated with kava and valerian: Singly and in combination. Hum Psychopharmacol 2001;16:353-6.
Giedke H, Breyer-Pfaff U. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000;33:239.
Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985;2:144-8.
Barton DL, Atherton PJ, Bauer BA, Moore DF Jr., Mattar BI, Lavasseur BI, et al.
The use of valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: A phase III randomized, placebo-controlled, double-blind study (NCCTG trial, N01C5). J Support Oncol 2011;9:24-31.
Morin CM, Koetter U, Bastien C. Valerian-hops combination and diphenhydramine for treating insomnia: A randomized placebo-controlled clinical trial. Alter Med Rev 2006;11:73-4.
Shinomiya K, Fujimura K, Kim Y, Kamei C. Effects of valerian extract on the sleep-wake cycle in sleep-disturbed rats. Acta Med Okayama 2005;59:89-92.
Santos MS, Ferreira F, Faro C, Pires E, Carvalho AP, Cunha AP, et al.
The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H] GABA release in synaptosomes. Planta Med 1994;60:475-6.
Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3 H] flunitrazepam binding, synaptosomal [3 H] GABA uptake, and hippocampal [3 H] GABA release. Neurochem Res 1999;24:1373-8.
Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro
. Brain Res Mol Brain Res 2005;138:191-7.